Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Poll|August 24, 2020
Poll: Psychiatrists and the 2020 Presidential Election
Author(s)Heidi Anne Duerr, MPH
Do you live by the old adage not to discuss religion or politics? Or, do you welcome controversy and let the chips fall where they may?
Advertisement
Between the Goldwater Rule and boundary issues, it can be tricky for the field and individual psychiatrists to address issues like politics and election anxiety.
How do you handle these discussions in your practice and life?
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5